|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 USD | +0.82% |
|
-1.60% | -45.38% |
| Mar. 20 | ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals | CI |
| Mar. 07 | Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing | MT |
Aurinia Pharmaceuticals Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 45.1 million compared to USD 28.44 million a year ago. Net loss was USD 26.88 million compared to USD 26.05 million a year ago.
Basic loss per share from continuing operations was USD 0.19 compared to USD 0.18 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -45.38% | 710M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AURINIA PHARMACEUTICALS INC. 
